Overview
Celemics’ G-Mendeliome Clinical Exome Sequencing (CES) Panel is
designed to overcome the limitations of analyzing clinical diseases
with conventional whole exome sequencing
genetic variations within target genes in the human genome. The G-Mendeliome CES panel includes clinically significant genes used in various other panels as well as additional clinically relevant genes, allowing customers to cost-effectively obtain comprehensive information of mutations for their genes of interest.
Features &
Benefits
-
- Comprehensive genomic profiling of a variety of genetic diseases
- Includes 7,000 genes associated with clinically significant genetic diseases
-
- A wide range of target regions
- Includes several clinically significant regions not covered by competitor's panels
-
- Cost-effective analysis
- Able to provide accurate analysis with reduced sequencing
costs compared to WES
Performance
Design of G-Mendeliome CES Panel and Comparison Data
G-Mendeliome CES Panel
Company A + Company B + over 70 genes
The CES Panel was developed from the needs of GC Genome,
the largest clinical NGS service provider in South Korea
to solve the problem of poor diagnosis and high costs
Comparison Data : ZNF419 gene
Comparison Data: COL6A5 gene
Using Celemics' in-house manufacturing and probe design system, customers can request the sequencing of homolog regions as well as hard-to-capture regions.
The comparison data showed obtained sequencing reads for ZNF419 and COL6A5 genes which are commonly masked in competitor's panels
G-Mendeliome CES Target Diseases
G-Mendeliome CES panel contains around 7,000 disease-related genes as target regions. The related diseases are listed in the table below.
Applications
-
Somatic cancer related fields
-
Research for Inherited disease